Unknown PHASE2 INTERVENTIONAL 2-arm NCT04869579

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients. (SeCOVID)

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients

Sponsor: CHRISTUS Health

Conditions Covid19

Interventions Placebo Selenium (as Selenious Acid)

Updated 5 times since 2021 Last updated: Jul 30, 2021 Started: Aug 15, 2021 Primary completion: Nov 15, 2021 Completion: Dec 15, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Covid19 and is currently ongoing. CHRISTUS Health leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Sep 2021 — Aug 2023 [monthly]

Not Yet Recruiting PHASE2
Jun 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CHRISTUS Health
Pharco Pharmaceuticals

Data source: CHRISTUS Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Longview, United States